中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 12
Dec.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(12): 2469-2473

The standardized diagnosis and treatment of incidental gallbladder carcinoma should be taken seriously

DOI: 10.12449/JCH251205

  • Department of Biliary Surgery，Institute of Biliary Tract Diseases，Zhongshan Hospital，Fudan University，Shanghai 200030，China

More Information
  • Corresponding author: LIU Houbao， liuhbao@163.com （ORCID： 0000-0003-0608-6522）
  • Received Date: 2025-10-23
  • Accepted Date: 2025-11-05
  • Published Date: 2025-12-25
    Abstract
  • Incidental gallbladder cancer （IGBC） refers to gallbladder cancer discovered incidentally during pathological examination after cholecystectomy for benign gallbladder diseases， and characterized by a high rate of missed diagnosis before surgery， wide staging variability， and complex treatment decision-making， IGBC poses a significant challenge in biliary tract oncology. With reference to existing evidence， this article systematically reviews the epidemiology， pathogenesis， diagnostic status， and treatment strategies of IGBC， analyzes existing bottlenecks in diagnosis and treatment， and proposes the future prospects from the aspects of precise early diagnosis， individualized treatment guided by molecular subtyping， and establishment of multidisciplinary collaboration models， in order to provide a reference for clinical practice and research.

     

    • FullText(HTML)
  • loading
    • References(47)
  • [1]
    ROA JC, GARCÍA P, KAPOOR VK, et al. Gallbladder cancer[J]. Nat Rev Dis Primers, 2022, 8: 69. DOI: 10.1038/s41572-022-00398-y.
    [2]
    ALABI A, ARVIND AD, PAWA N, et al. Incidental gallbladder cancer: Routine versus selective histological examination after cholecystectomy[J]. Surg J(N Y), 2021, 7( 1): e22- e25. DOI: 10.1055/s-0040-1722175.
    [3]
    APODACA-RUEDA M, CAZZO E, DE-CARVALHO RB, et al. Prevalência do câncer de vesícula biliar em pacientes submetidos à colecistectomia: Experiência do hospital de clínicas da faculdade de ciências médicas da universidade estadual de campinas-UNICAMP[J]. Rev Col Bras Cir, 2017, 44( 3): 252- 256. DOI: 10.1590/0100-699-12017003005.
    [4]
    CHOI KS. Clinical characteristics of incidental or unsuspected gallbladder cancers diagnosed during or after cholecystectomy: A systematic review and meta-analysis[J]. World J Gastroenterol, 2015, 21( 4): 1315. DOI: 10.3748/wjg.v21.i4.1315.
    [5]
    FEO CF, GINESU GC, FANCELLU A, et al. Current management of incidental gallbladder cancer: A review[J]. Int J Surg, 2022, 98: 106234. DOI: 10.1016/j.ijsu.2022.106234.
    [6]
    PITT SC, JIN LX, HALL BL, et al. Incidental gallbladder cancer at cholecystectomy: When should the surgeon be suspicious?[J]. Ann Surg, 2014, 260( 1): 128- 133. DOI: 10.1097/sla.0000000000000485.
    [7]
    SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
    [8]
    LEMROW SM, PERDUE DG, STEWART SL, et al. Gallbladder cancer incidence among American indians and Alaska natives, US, 1999-2004[J]. Cancer, 2008, 113( S5): 1266- 1273. DOI: 10.1002/cncr.23737.
    [9]
    DUTTA U, BUSH N, KALSI D, et al. Epidemiology of gallbladder cancer in India[J]. Chin Clin Oncol, 2019, 8( 4): 33. DOI: 10.21037/cco.2019.08.03.
    [10]
    KAPOOR VK, SINGH R, BEHARI A, et al. Anticipatory extended cholecystectomy: the‘Lucknow’ approach for thick walled gall bladder with low suspicion of cancer[J]. Chin Clin Oncol, 2016, 5( 1): 8. DOI: 10.3978/j.issn.2304-3865.2016.02.07.
    [11]
    ZAIDI MY, ABOU-ALFA GK, ETHUN CG, et al. Evaluation and management of incidental gallbladder cancer[J]. Chin Clin Oncol, 2019, 8( 4): 37. DOI: 10.21037/cco.2019.07.01.
    [12]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases[J]. J Hepatol, 2009, 51( 2): 237- 267. DOI: 10.1016/j.jhep.2009.04.009.
    [13]
    CHAPMAN R, FEVERY J, KALLOO A, et al. Diagnosis and management of primary sclerosing cholangitis[J]. Hepatology, 2010, 51( 2): 660- 678. DOI: 10.1002/hep.23294.
    [14]
    KANG JS, HONG SY, HAN Y, et al. Limits of serum carcinoembryonic antigen and carbohydrate antigen 19-9 as the diagnosis of gallbladder cancer[J]. Ann Surg Treat Res, 2021, 101( 5): 266. DOI: 10.4174/astr.2021.101.5.266.
    [15]
    ARGON A, YAĞCı A, TAŞLı F, et al. A different perspective on macroscopic sampling of cholecystectomy specimens[J]. Korean J Pathol, 2013, 47( 6): 519. DOI: 10.4132/koreanjpathol.2013.47.6.519.
    [16]
    FEO CF, COSSU ML, GINESU GC, et al. Perineural infiltration as a prognostic factor in surgically treated gallbladder cancer A single center experience and literature review[J]. Ann Ital Chir, 2017, 88: 485- 490.
    [17]
    CHERKASSKY L, D’ANGELICA M. Gallbladder cancer[J]. Surg Oncol Clin N Am, 2019, 28( 4): 619- 630. DOI: 10.1016/j.soc.2019.06.005.
    [18]
    ISAMBERT M, LEUX C, MÉTAIRIE S, et al. Incidentally-discovered gallbladder cancer: When, why and which reoperation?[J]. J Visc Surg, 2011, 148( 2): e77- e84. DOI: 10.1016/j.jviscsurg.2011.02.005.
    [19]
    ADSAY V, JANG KT, ROA JC, et al. Intracholecystic papillary-tubular neoplasms(ICPN) of the gallbladder(neoplastic polyps, adenomas, and papillary neoplasms that are ≥1.0 Cm): Clinicopathologic and immunohistochemical analysis of 123 cases[J]. Am J Surg Pathol, 2012, 36( 9): 1279- 1301. DOI: 10.1097/pas.0b013e318262787c.
    [20]
    YOSHIDA M, YUKAWA H, HAYASHI K, et al. Clinical impact of bile-derived exosomal microRNAs as novel diagnostic and prognostic biomarkers for biliary tract cancers[J]. Cancer Sci, 2023, 114( 1): 295- 305. DOI: 10.1111/cas.15597.
    [21]
    HUANG JJ, PATEL HK, BOAKYE D, et al. Worldwide distribution, associated factors, and trends of gallbladder cancer: A global country-level analysis[J]. Cancer Lett, 2021, 521: 238- 251. DOI: 10.1016/j.canlet.2021.09.004.
    [22]
    HUNDAL R. SHAFFER EA, Gallbladder cancer: epidemiology and outcome[J]. Clin Epidemiol, 2014, 6: 99- 109. DOI: 10.2147/CLEP.S37357.
    [23]
    ROSA L, LOBOS-GONZÁLEZ L, MUÑOZ-DURANGO N, et al. Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia[J]. Mol Oncol, 2020, 14( 11): 2834- 2852. DOI: 10.1002/1878-0261.12766.
    [24]
    ESPINOZA JA, BIZAMA C, GARCÍA P, et al. The inflammatory inception of gallbladder cancer[J]. Biochim Biophys Acta BBA Rev Cancer, 2016, 1865( 2): 245- 254. DOI: 10.1016/j.bbcan.2016.03.004.
    [25]
    MALHOTRA R, MANOHARAN N, SHUKLA NK, et al. Gallbladder cancer incidence in Delhi urban: A 25-year trend analysis[J]. Indian J Cancer, 2017, 54( 4): 673. DOI: 10.4103/ijc.ijc_393_17.
    [26]
    IYER P, BARRETO SG, SAHOO B, et al. Non-typhoidal Salmonella DNA traces in gallbladder cancer[J]. Infect Agents Cancer, 2016, 11( 1): 12. DOI: 10.1186/s13027-016-0057-x.
    [27]
    HEMMINKI K, FÖRSTI A, HEMMINKI O, et al. Long-term incidence and survival trends in cancer of the gallbladder and extrahepatic bile ducts in Denmark, Finland, Norway and Sweden with etiological implications related to Thorotrast[J]. Int J Cancer, 2022, 151( 2): 200- 208. DOI: 10.1002/ijc.33980.
    [28]
    JAIN K, MOHAPATRA T, DAS P, et al. Sequential occurrence of preneoplastic lesions and accumulation of loss of heterozygosity in patients with gallbladder stones suggest causal association with gallbladder cancer[J]. Ann Surg, 2014, 260( 6): 1073- 1080. DOI: 10.1097/sla.000000-0000000495.
    [29]
    BARRETO SG, DUTT A, CHAUDHARY A. A genetic model for gallbladder carcinogenesis and its dissemination[J]. Ann Oncol, 2014, 25( 6): 1086- 1097. DOI: 10.1093/annonc/mdu006.
    [30]
    IYER P, SHRIKHANDE SV, RANJAN M, et al. ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer[J]. Int J Cancer, 2019, 144( 8): 2008- 2019. DOI: 10.1002/ijc.31916.
    [31]
    KAWAKAMI S, TAKANO S, FUKASAWA M, et al. Stepwise correlation of TP53 mutations from pancreaticobiliary maljunction to gallbladder carcinoma: A retrospective study[J]. BMC Cancer, 2021, 21( 1): 1245. DOI: 10.1186/s12885-021-09000-2.
    [32]
    NEPAL C, ZHU B, O’ROURKE CJ, et al. Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes[J]. J Hepatol, 2021, 74( 5): 1132- 1144. DOI: 10.1016/j.jhep.2020.11.033.
    [33]
    ROA JC, ROA I, CORREA P, et al. Microsatellite instability in preneoplastic and neoplastic lesions of the gallbladder[J]. J Gastroenterol, 2005, 40( 1): 79- 86. DOI: 10.1007/s00535-004-1497-4.
    [34]
    ABDEL-WAHAB R, YAP TA, MADISON R, et al. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer[J]. Sci Rep, 2020, 10: 22087. DOI: 10.1038/s41598-020-77939-6.
    [35]
    BERCHUCK JE, FACCHINETTI F, DITORO DF, et al. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer[J]. Ann Oncol, 2022, 33( 12): 1269- 1283. DOI: 10.1016/j.annonc.2022.09.150.
    [36]
    PRIYA TP, KAPOOR VK, KRISHNANI N, et al. Role of E-cadherin gene in gall bladder cancer and its precursor lesions[J]. Virchows Arch, 2010, 456( 5): 507- 514. DOI: 10.1007/s00428-010-0908-6.
    [37]
    WISTUBA II, ASHFAQ R, MAITRA A, et al. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma[J]. Am J Pathol, 2002, 160( 6): 2073- 2079. DOI: 10.1016/s0002-9440(10)61157-1.
    [38]
    LEE SE, KIM KS, KIM WB, et al. Practical guidelines for the surgical treatment of gallbladder cancer[J]. J Korean Med Sci, 2014, 29( 10): 1333. DOI: 10.3346/jkms.2014.29.10.1333.
    [39]
    UTSUMI M, AOKI H, KUNITOMO T, et al. Evaluation of surgical treatment for incidental gallbladder carcinoma diagnosed during or after laparoscopic cholecystectomy: Single center results[J]. BMC Res Notes, 2017, 10( 1): 56. DOI: 10.1186/s13104-017-2387-1.
    [40]
    SØREIDE K, GUEST RV, HARRISON EM, et al. Systematic review of management of incidental gallbladder cancer after cholecystectomy[J]. J Br Surg, 2019, 106( 1): 32- 45. DOI: 10.1002/bjs.11035.
    [41]
    XU C, HU MT, XIE ZH, et al. Clinical efficacy analysis of secondary radical resection for incidental gallbladder cancer after laparoscopic cholecystectomy[J]. Chin J Prac Surg, 2023, 43( 4): 405- 410. DOI: 10.19538/j.cjps.issn1005-2208.2023.04.08.
    [42]
    SHINDOH J, DE ARETXABALA X, ALOIA TA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: An international multicenter study[J]. Ann Surg, 2015, 261( 4): 733- 739. DOI: 10.1097/sla.0000000000000728.
    [43]
    MORIS D, PALTA M, KIM C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians[J]. CA A Cancer J Clin, 2023, 73( 2): 198- 222. DOI: 10.3322/caac.21759.
    [44]
    NAM AR, KIM JW, CHA YJ, et al. Therapeutic implication of HER2 in advanced biliary tract cancer[J]. Oncotarget, 2016, 7( 36): 58007- 58021. DOI: 10.18632/oncotarget.11157.
    [45]
    HEZEL AF, DESHPANDE V, ZHU AX. Genetics of biliary tract cancers and emerging targeted therapies[J]. J Clin Oncol, 2010, 28( 21): 3531- 3540. DOI: 10.1200/jco.2009.27.4787.
    [46]
    WU XH, MAO YM, XU N, et al. Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158 final analysis[J]. Adv Ther, 2025, 42( 5): 2480- 2489. DOI: 10.1007/s12325-025-03142-6.
    [47]
    HYMAN DM, TRAN B, PAZ-ARES L, et al. Combined PIK3CA and FGFR inhibition with alpelisib and infigratinib in patients with PIK3CA-mutant solid tumors, with or without FGFR alterations[J]. JCO Precis Oncol, 2019( 3): 1- 13. DOI: 10.1200/po.19.00221.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (43) PDF downloads(28) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return